Natera, Inc.

Canaccord Genuity acts as Financial Advisor for US$287.5 million public offering of common stock by Natera, Inc.

Canaccord Genuity is pleased to announce that on September 15, 2020, it completed a public offering of common stock for Natera, Inc. (NASDAQ: NTRA) (the “Company”). The Company issued a total of 4,791,665 shares of its common stock at a price to the public of $60.00 per share, which includes the full exercise of the underwriters’ overallotment option. The gross proceeds to the Company, before deducting the underwriting discounts and commissions and estimated offering expenses, were approximately $287.5 million. The Company intends to use the net proceeds from the offering for working capital and general corporate purposes, to fund investments in research and development and product development and to fund acquisitions of complementary businesses, technologies or other assets.

Canaccord Genuity acted as Financial Advisor for the offering.

Natera, Inc. develops proprietary bioinformatics and molecular technologies to analyze DNA. The Company’s novel molecular assays reliably measure many informative regions across the genome. Natera’s advanced statistical algorithms then combine the measurements from these assays with data available from the broader scientific community to identify genetic variations covering a wide range of serious conditions with best-in-class accuracy and coverage.